SV2004000109A - Combinacion de inhibidores de mtp e inhibidores de hmg-coa reductasa y su uso en medicamentos ref.lea 33846-sv - Google Patents

Combinacion de inhibidores de mtp e inhibidores de hmg-coa reductasa y su uso en medicamentos ref.lea 33846-sv

Info

Publication number
SV2004000109A
SV2004000109A SV2000000109A SV2000000109A SV2004000109A SV 2004000109 A SV2004000109 A SV 2004000109A SV 2000000109 A SV2000000109 A SV 2000000109A SV 2000000109 A SV2000000109 A SV 2000000109A SV 2004000109 A SV2004000109 A SV 2004000109A
Authority
SV
El Salvador
Prior art keywords
inhibitors
combination
hmg
lea
ref
Prior art date
Application number
SV2000000109A
Other languages
English (en)
Inventor
Rudi Grutzmann
Ulrich Muller
Hilmar Bischoff
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of SV2004000109A publication Critical patent/SV2004000109A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION SE REFIERE AL USO DE UNA COMBINACION DE AL MENOS UN INHIBIDOR DE MTP SELECCIONADO (COMPONENTE A) Y UN INHIBIDOR DE HMG-COA REDUCTASA (COMPONENTE B) PARA LA LUCHA CONTRA ENFERMEDADES DEL SISTEMA CARDIOCIRCULATORIO,A MEDICAMENTOS QUE CONTIENEN ESTA COMBINACION Y A SU OBTENCION.
SV2000000109A 1999-06-25 2000-06-23 Combinacion de inhibidores de mtp e inhibidores de hmg-coa reductasa y su uso en medicamentos ref.lea 33846-sv SV2004000109A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19929065A DE19929065A1 (de) 1999-06-25 1999-06-25 Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln

Publications (1)

Publication Number Publication Date
SV2004000109A true SV2004000109A (es) 2004-05-07

Family

ID=7912459

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2000000109A SV2004000109A (es) 1999-06-25 2000-06-23 Combinacion de inhibidores de mtp e inhibidores de hmg-coa reductasa y su uso en medicamentos ref.lea 33846-sv

Country Status (12)

Country Link
EP (1) EP1196194A2 (es)
JP (1) JP2003503342A (es)
AR (1) AR028996A1 (es)
AU (1) AU5680900A (es)
CA (1) CA2376881A1 (es)
DE (1) DE19929065A1 (es)
DO (1) DOP2000000022A (es)
GT (1) GT200000099A (es)
PE (1) PE20010302A1 (es)
SV (1) SV2004000109A (es)
UY (1) UY26218A1 (es)
WO (1) WO2001000183A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10030375A1 (de) * 2000-06-21 2002-01-03 Bayer Ag Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
CN1943786A (zh) * 2002-02-28 2007-04-11 日本烟草产业株式会社 酯化合物及其医药用途
WO2005021486A1 (ja) 2003-08-29 2005-03-10 Japan Tobacco Inc. エステル誘導体及びその医薬用途
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
FR2884831B1 (fr) * 2005-04-22 2007-08-10 Merck Sante Soc Par Actions Si Methode de criblage de composes inhibiteurs de la mtp
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
CN109053927A (zh) * 2018-08-08 2018-12-21 中山大学 一种含维生素b12基团的两亲性海藻酸钠衍生物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
DE19546918A1 (de) * 1995-12-15 1997-06-19 Bayer Ag Bicyclische Heterocyclen
DE19546919A1 (de) * 1995-12-15 1997-06-19 Bayer Ag N-Heterocyclisch substituierte Phenylessigsäure-Derivate
DE19615265A1 (de) * 1996-04-18 1997-12-04 Bayer Ag Neue Pyridazino-, Pyrimido-, Pyrazino- und Triazino-indole
BR9714364A (pt) * 1996-11-27 2000-03-21 Pfizer Amidas inibidoras da secreção de apo b/mtp
CA2286341A1 (en) * 1997-05-01 1998-11-12 John R. Ii Wetterau Mtp inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels

Also Published As

Publication number Publication date
GT200000099A (es) 2001-12-13
PE20010302A1 (es) 2001-04-12
CA2376881A1 (en) 2001-01-04
DOP2000000022A (es) 2008-08-15
WO2001000183A2 (de) 2001-01-04
EP1196194A2 (de) 2002-04-17
WO2001000183A3 (de) 2001-05-10
UY26218A1 (es) 2001-01-31
DE19929065A1 (de) 2000-12-28
AU5680900A (en) 2001-01-31
AR028996A1 (es) 2003-06-04
JP2003503342A (ja) 2003-01-28

Similar Documents

Publication Publication Date Title
DOP2000000022A (es) Combinacion de inhibidores de mtp e inhibidores de hmg-coa reductasa y su uso en medicametos.
PA8493401A1 (es) Uso de inhibidores de cyp2d6 en terapias de combinacion
DOP2019000185A (es) Una formulación sólida de dosificación farmacéutica
AR045179A1 (es) Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer
PA8506101A1 (es) Uso de un compuesto acat para fabricar una composicion farmaceutica
CR7942A (es) Combinaciones antineoplasticas que comprenden un derivado de rapamicina y un inhibidor de aromatasa
PA8513601A1 (es) Composiciones farmaceuticas de inhibidores de la glucogenofosforilasa
HN2002000150A (es) Agentes antibacteriano
PT1328269E (pt) Associacao de um antagonista do receptor cb1 e de sibutramina composicoes farmaceuticas que os contem e sua utilizacao para o tratamento da obesidade
PT1424893E (pt) Mistura fungicida que contem derivados de arilamidina.
CL2004000416A1 (es) Compuestos heterociclicos nitrogenados; composicion farmaceutica; y uso del compuesto para tratar o prevenir una condicion mediada por p38, que consiste en una enfermedad inflamatoria, autoinmune, virosica o neurodegenerativa.
HN2001000146A (es) Derivados de pirazol
HN2003000227A (es) Inhibidores de quinasas
CL2007000355A1 (es) Combinacion que comprende un inhibidor de quinasas dependiente de ciclinas, un anticuerpo que inhibe un factor de crecimiento y un agente antimitotico; composicion farmaceutica que la comprende; y su uso para tratar un trastorno proliferativo.
GT200000077A (es) Sal mutua de amlodipino y atorvastatina
ECSP044981A (es) Composicion oftalmica que comprende ascomicina
CL2004000366A1 (es) USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
BR0002953A (pt) Composições e tratamento para complicações diabéticas
AR030140A1 (es) Composiciones derivadas de la 2-piridinamina y metodos relacionados
ES2132539T3 (es) Composiciones insecticidas sinergicas.
ES2196559T3 (es) Inhibidores de farnesil transferasa en combinacion con inhibidores de hmg coa reductasa para el tratamiento del cancer.
SV2003001179A (es) Formulacion de 2-metilo-tieno-benzodiacepina liofilizada ref. x-11102
BR0002957A (pt) Combinações de inbidores de aldose-redutase e inibidores de ciclooxigenase-2 seletivos
GT200200244A (es) Composicion intensiva de herbicida
IT1318401B1 (it) Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono.